Biomarin Pharmaceutical vs Vertex Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Biomarin Pharmaceutical Inc (BMRN)

Q3 202623 Jun – 30 Sep 2026

▲4

BioMarin advances Voxzogo, adds Alesta, settles patent, raises guidance

Voxzogo nears full FDA approval and $1B revenue Voxzogo moved toward full FDA approval, with a decision expected February 2027, and approached $1 billion in annual revenue. Positive Phase 3 data in hypochondroplasia supports a filing to expand its label.
Voxzogo is BioMarin's key growth driver, and its regulatory and commercial progress directly boosts investor confidence.
Alesta acquisition adds oral hypophosphatasia therapy BioMarin acquired Alesta, gaining ALE1, a potential first oral treatment for hypophosphatasia. The deal expands the pipeline into a new rare disease area, though ALE1 remains unproven.
The acquisition adds a new pipeline asset and strategic growth opportunity, which can lift investor sentiment.
Patent settlement with Ascendis secures royalties BioMarin settled patent litigation with Ascendis, securing royalties on rival Yuviwel through 2030. This removes legal uncertainty and provides a finite but predictable revenue stream.
The settlement eliminates a legal overhang and adds royalty income, improving financial visibility.
Raised guidance and Amicus synergies improve outlook BioMarin raised its financial guidance, targeted $200 million in annual savings from Amicus synergies, and accelerated deleveraging. An AI enzyme partnership with Profluent adds long-term pipeline potential.
These financial and strategic moves strengthen the company's outlook and support the stock.

September 202631 Aug – 30 Sep 2026

▲4

BioMarin settles patent fight, closes Alesta, and expands VOXZOGO

Patent settlement secures royalties on rival Yuviwel BioMarin settled global patent disputes with Ascendis, winning 20% US and 18% EU/Brazil/South Korea royalties on Yuviwel sales through May 2030. This turns a costly legal fight into a steady income stream and removes uncertainty, lifting the stock.
This is the period's biggest new event, directly adding royalty revenue and removing litigation risk.
Alesta acquisition adds oral hypophosphatasia drug BioMarin completed its purchase of Alesta Therapeutics, adding ALE1, a potential first oral therapy for hypophosphatasia, to its pipeline. This strengthens the rare bone disease portfolio and gives investors a new growth candidate beyond existing drugs.
A new pipeline asset expands future revenue potential and shows management is investing in growth.
VOXZOGO nears $1B, Amicus synergies on track VOXZOGO grew patients 20% quarterly and is expected to hit $1 billion in revenue this year, while Amicus integration targets $200 million in annual cost savings and faster debt reduction. Strong sales plus cost cuts boost profits and cash flow.
This shows the core growth driver and merger savings that directly improve earnings and balance sheet.
VOXZOGO hypochondroplasia data and AI enzyme deal BioMarin reported positive Phase 3 results for VOXZOGO in hypochondroplasia and filed for FDA approval, expanding its label. It also partnered with Profluent to use AI to design new enzyme therapies, adding long-term pipeline potential.
New indication and AI partnership broaden the franchise and future pipeline, supporting the growth story.

Latest31 Aug – 30 Sep 2026

▲4

BioMarin settles patent fight, closes Alesta, and expands VOXZOGO

Patent settlement secures royalties on rival Yuviwel BioMarin settled global patent disputes with Ascendis, winning 20% US and 18% EU/Brazil/South Korea royalties on Yuviwel sales through May 2030. This turns a costly legal fight into a steady income stream and removes uncertainty, lifting the stock.
This is the period's biggest new event, directly adding royalty revenue and removing litigation risk.
Alesta acquisition adds oral hypophosphatasia drug BioMarin completed its purchase of Alesta Therapeutics, adding ALE1, a potential first oral therapy for hypophosphatasia, to its pipeline. This strengthens the rare bone disease portfolio and gives investors a new growth candidate beyond existing drugs.
A new pipeline asset expands future revenue potential and shows management is investing in growth.
VOXZOGO nears $1B, Amicus synergies on track VOXZOGO grew patients 20% quarterly and is expected to hit $1 billion in revenue this year, while Amicus integration targets $200 million in annual cost savings and faster debt reduction. Strong sales plus cost cuts boost profits and cash flow.
This shows the core growth driver and merger savings that directly improve earnings and balance sheet.
VOXZOGO hypochondroplasia data and AI enzyme deal BioMarin reported positive Phase 3 results for VOXZOGO in hypochondroplasia and filed for FDA approval, expanding its label. It also partnered with Profluent to use AI to design new enzyme therapies, adding long-term pipeline potential.
New indication and AI partnership broaden the franchise and future pipeline, supporting the growth story.

July 202623 Jun – 18 Aug 2026

▲4

BioMarin's Voxzogo Expansion, Amicus Deal, and Alesta Buy Drive Growth

Voxzogo Regulatory Progress The FDA accepted BioMarin's application for full approval of Voxzogo, with a decision expected by February 2027. This moves the drug closer to broader use, which could boost sales and reassure investors about the company's growth path.
This is a key regulatory milestone that directly affects future revenue from BioMarin's flagship drug.
Raised Guidance and Faster Deleveraging BioMarin raised its 2025 revenue and earnings guidance and now expects to cut debt faster than planned, thanks to the Amicus acquisition. This signals stronger financial health and growth from new products like Galafold and Pombiliti/Opfolda.
It shows improved financial performance and balance sheet strength, which can lift investor confidence and the stock price.
Alesta Acquisition Adds Oral Therapy BioMarin agreed to buy Alesta Therapeutics for $275 million upfront to gain ALE1, a potential first oral treatment for hypophosphatasia. This expands the pipeline into a new disease area with a convenient pill form, which could drive future growth.
It represents a strategic pipeline expansion that may open a new market and diversify revenue.
Sustained Voxzogo Data in Hypochondroplasia New three-year data showed Voxzogo continued to improve growth in children with hypochondroplasia, and BioMarin plans to file for approval in this new use. This could significantly expand the patient population and sales potential.
It supports label expansion into a larger market, directly impacting future revenue growth.

23 Jun – 18 Aug 2026

▲4

BioMarin's Voxzogo Expansion, Amicus Deal, and Alesta Buy Drive Growth

Voxzogo Regulatory Progress The FDA accepted BioMarin's application for full approval of Voxzogo, with a decision expected by February 2027. This moves the drug closer to broader use, which could boost sales and reassure investors about the company's growth path.
This is a key regulatory milestone that directly affects future revenue from BioMarin's flagship drug.
Raised Guidance and Faster Deleveraging BioMarin raised its 2025 revenue and earnings guidance and now expects to cut debt faster than planned, thanks to the Amicus acquisition. This signals stronger financial health and growth from new products like Galafold and Pombiliti/Opfolda.
It shows improved financial performance and balance sheet strength, which can lift investor confidence and the stock price.
Alesta Acquisition Adds Oral Therapy BioMarin agreed to buy Alesta Therapeutics for $275 million upfront to gain ALE1, a potential first oral treatment for hypophosphatasia. This expands the pipeline into a new disease area with a convenient pill form, which could drive future growth.
It represents a strategic pipeline expansion that may open a new market and diversify revenue.
Sustained Voxzogo Data in Hypochondroplasia New three-year data showed Voxzogo continued to improve growth in children with hypochondroplasia, and BioMarin plans to file for approval in this new use. This could significantly expand the patient population and sales potential.
It supports label expansion into a larger market, directly impacting future revenue growth.

Vertex Pharmaceuticals Inc (VRTX)

Q3 202611 Jul – 24 Sep 2026

▲3▼1

Vertex beats on revenue, raises guidance, but faces new competition

Strong Q2 results and raised guidance Vertex reported Q2 revenue up 12% to $3.3 billion, raised full-year guidance to $13.1–13.2 billion, and announced a $1.42 billion share buyback. These results show the core business is performing well and returning cash to shareholders.
This is new financial information that directly reflects the company's current performance and outlook.
Crinetics acquisition adds up to $5B peak sales The $10 billion Crinetics acquisition is expected to add up to $5 billion in peak annual sales and diversify Vertex beyond cystic fibrosis. This strategic move could drive long-term growth and reduce reliance on a single franchise.
This is a new detail about the acquisition's potential impact, not previously reported.
Casgevy pediatric expansion and inaxaplin data Casgevy's approval for young children and positive inaxaplin kidney data strengthen Vertex's pipeline. These advances expand the patient population and support future revenue streams in gene therapy and kidney disease.
These are new clinical and regulatory developments that bolster the bull case.
Novartis competition and premium valuation Novartis' Fabhalta is already fully approved for IgA nephropathy, ahead of Vertex's povetacicept FDA decision in November 2026. Vertex trades at a premium with slipping 2026 estimates, and the high Crinetics premium raises execution risk.
This highlights real competitive and valuation risks that could pressure the stock.

September 202631 Aug – 24 Sep 2026

▲3

Vertex's $10B Crinetics Buy and Kidney Pipeline Progress Drive Upside

Crinetics acquisition diversifies beyond CF Vertex completed its $10 billion purchase of Crinetics, adding Palsonify (approved for acromegaly) and atumelnant (late-stage for a hormone disorder). This opens a new treatment area beyond cystic fibrosis, supporting long-term growth and a higher stock price.
This is the period's biggest new event, directly expanding Vertex's business and analyst price targets.
Morgan Stanley starts with Overweight and $665 target Morgan Stanley resumed coverage with an Overweight rating and a $665 price target, citing the Crinetics deal's diversification. The analyst raised Vertex's long-term revenue growth estimate to 13.8% from 12.1%, which helps justify a higher valuation.
A major analyst upgrade directly influences investor sentiment and price targets.
Positive kidney drug data and FDA filing progress Vertex reported positive Phase IIb data for inaxaplin in a kidney disease, showing large reductions in protein in urine, and completed enrollment in a pivotal study. The FDA also accepted its filing for povetacicept, with a decision due Nov. 30, 2026. These advance a new kidney franchise.
New clinical and regulatory progress adds a potential multi-billion-dollar revenue stream beyond CF.
Competition in kidney disease and high deal premium Vertex's kidney pipeline faces competition: Novartis' Fabhalta and other drugs are already approved for IgA nephropathy. Also, Vertex paid a roughly 100% premium for Crinetics, raising the bar for success. These factors could limit upside if execution disappoints.
Provides a fair counterweight to the positive news, highlighting real risks.

Latest31 Aug – 24 Sep 2026

▲3

Vertex's $10B Crinetics Buy and Kidney Pipeline Progress Drive Upside

Crinetics acquisition diversifies beyond CF Vertex completed its $10 billion purchase of Crinetics, adding Palsonify (approved for acromegaly) and atumelnant (late-stage for a hormone disorder). This opens a new treatment area beyond cystic fibrosis, supporting long-term growth and a higher stock price.
This is the period's biggest new event, directly expanding Vertex's business and analyst price targets.
Morgan Stanley starts with Overweight and $665 target Morgan Stanley resumed coverage with an Overweight rating and a $665 price target, citing the Crinetics deal's diversification. The analyst raised Vertex's long-term revenue growth estimate to 13.8% from 12.1%, which helps justify a higher valuation.
A major analyst upgrade directly influences investor sentiment and price targets.
Positive kidney drug data and FDA filing progress Vertex reported positive Phase IIb data for inaxaplin in a kidney disease, showing large reductions in protein in urine, and completed enrollment in a pivotal study. The FDA also accepted its filing for povetacicept, with a decision due Nov. 30, 2026. These advance a new kidney franchise.
New clinical and regulatory progress adds a potential multi-billion-dollar revenue stream beyond CF.
Competition in kidney disease and high deal premium Vertex's kidney pipeline faces competition: Novartis' Fabhalta and other drugs are already approved for IgA nephropathy. Also, Vertex paid a roughly 100% premium for Crinetics, raising the bar for success. These factors could limit upside if execution disappoints.
Provides a fair counterweight to the positive news, highlighting real risks.

August 20268 Aug – 26 Aug 2026

▲3

Vertex Rises as Rival CF Drug Fails and Guidance Climbs

Rival CF drug failure clears competitive threat Sionna's SION-719 failed its Phase 2a trial, and the company dropped the program. That removes a would-be competitor to Vertex's cystic fibrosis franchise, which brings in most of its revenue. Less competition means Vertex can keep its dominant share and pricing power, pushing the stock up.
This is the biggest new event of the period and directly lifts Vertex's core CF business.
Q2 revenue beat and raised 2026 guidance Vertex reported Q2 revenue of $3.33 billion, up 12.5% and above estimates, and raised full-year revenue guidance to $13.1–$13.2 billion. It also completed a $1.42 billion share buyback. Strong sales and a brighter outlook support a higher stock price.
The quarter's results and guidance are the core financial driver behind the stock's move.
Non-CF products gaining traction Newer non-CF drugs Journavx and Casgevy posted combined Q2 sales of $126 million, and Vertex expects non-CF revenue to top $500 million in 2026, up about 185%. This shows the company is building growth beyond cystic fibrosis, which supports a higher valuation.
It shows the post-CF growth story is real, a key reason investors are paying up for the stock.
Kidney competition and valuation keep a lid on gains Novartis' Fabhalta is already fully approved for IgA nephropathy, while Vertex's povetacicept faces an FDA decision by Nov. 30, 2026. Vertex also trades at a premium to peers, and 2026 earnings estimates have slipped. These are real counterweights that could limit upside.
It gives the fair counterweight: competition and a rich valuation could cap further gains.

8 Aug – 26 Aug 2026

▲3

Vertex Rises as Rival CF Drug Fails and Guidance Climbs

Rival CF drug failure clears competitive threat Sionna's SION-719 failed its Phase 2a trial, and the company dropped the program. That removes a would-be competitor to Vertex's cystic fibrosis franchise, which brings in most of its revenue. Less competition means Vertex can keep its dominant share and pricing power, pushing the stock up.
This is the biggest new event of the period and directly lifts Vertex's core CF business.
Q2 revenue beat and raised 2026 guidance Vertex reported Q2 revenue of $3.33 billion, up 12.5% and above estimates, and raised full-year revenue guidance to $13.1–$13.2 billion. It also completed a $1.42 billion share buyback. Strong sales and a brighter outlook support a higher stock price.
The quarter's results and guidance are the core financial driver behind the stock's move.
Non-CF products gaining traction Newer non-CF drugs Journavx and Casgevy posted combined Q2 sales of $126 million, and Vertex expects non-CF revenue to top $500 million in 2026, up about 185%. This shows the company is building growth beyond cystic fibrosis, which supports a higher valuation.
It shows the post-CF growth story is real, a key reason investors are paying up for the stock.
Kidney competition and valuation keep a lid on gains Novartis' Fabhalta is already fully approved for IgA nephropathy, while Vertex's povetacicept faces an FDA decision by Nov. 30, 2026. Vertex also trades at a premium to peers, and 2026 earnings estimates have slipped. These are real counterweights that could limit upside.
It gives the fair counterweight: competition and a rich valuation could cap further gains.

July 202611 Jul – 4 Aug 2026

▲3▼1

Vertex's Q2 beat and Crinetics deal drive growth, but kidney competition looms

Q2 revenue surges 12% to $3.3B, guidance raised Vertex reported Q2 revenue of $3.3 billion, up 12% year-over-year, driven by CF and newer products. Full-year guidance was raised to $13.1–13.2 billion, and EPS beat expectations. This strong financial performance supports a higher stock price by showing robust demand and execution.
This is the most recent and direct positive financial update, showing accelerating growth and raised outlook.
Crinetics acquisition adds $5B peak sales potential Vertex agreed to acquire Crinetics for $10 billion, gaining paltusotine (PALSONIFY) and atumelnant. The deal is expected to add up to $5 billion in peak revenue and diversify beyond CF. While it uses cash, the strategic fit and growth potential outweigh the cost.
This is a major strategic move that expands Vertex's rare disease portfolio and long-term growth prospects.
Novartis' Fabhalta full approval intensifies kidney competition The FDA granted full approval to Novartis' Fabhalta for IgA nephropathy, a direct competitor to Vertex's povetacicept (target action date Nov 30, 2026). This could limit povetacicept's market share and pricing power, posing a risk to Vertex's kidney pipeline.
This is a new competitive threat that could impact a key growth driver for Vertex.
Casgevy approval expanded to children as young as 2 The FDA expanded Casgevy's approval to treat children aged 2 and older with sickle cell disease or thalassemia. This broadens the eligible patient population and strengthens Vertex's gene therapy franchise, though real-world uptake and reimbursement will determine the actual revenue impact.
This regulatory win opens a new pediatric market for Casgevy, supporting long-term growth.

11 Jul – 4 Aug 2026

▲3▼1

Vertex's Q2 beat and Crinetics deal drive growth, but kidney competition looms

Q2 revenue surges 12% to $3.3B, guidance raised Vertex reported Q2 revenue of $3.3 billion, up 12% year-over-year, driven by CF and newer products. Full-year guidance was raised to $13.1–13.2 billion, and EPS beat expectations. This strong financial performance supports a higher stock price by showing robust demand and execution.
This is the most recent and direct positive financial update, showing accelerating growth and raised outlook.
Crinetics acquisition adds $5B peak sales potential Vertex agreed to acquire Crinetics for $10 billion, gaining paltusotine (PALSONIFY) and atumelnant. The deal is expected to add up to $5 billion in peak revenue and diversify beyond CF. While it uses cash, the strategic fit and growth potential outweigh the cost.
This is a major strategic move that expands Vertex's rare disease portfolio and long-term growth prospects.
Novartis' Fabhalta full approval intensifies kidney competition The FDA granted full approval to Novartis' Fabhalta for IgA nephropathy, a direct competitor to Vertex's povetacicept (target action date Nov 30, 2026). This could limit povetacicept's market share and pricing power, posing a risk to Vertex's kidney pipeline.
This is a new competitive threat that could impact a key growth driver for Vertex.
Casgevy approval expanded to children as young as 2 The FDA expanded Casgevy's approval to treat children aged 2 and older with sickle cell disease or thalassemia. This broadens the eligible patient population and strengthens Vertex's gene therapy franchise, though real-world uptake and reimbursement will determine the actual revenue impact.
This regulatory win opens a new pediatric market for Casgevy, supporting long-term growth.

Q2 202619 Jun – 10 Jul 2026

▲4

Vertex expands kidney, gene therapy, and rare disease reach

Kidney pipeline could add billions Vertex's kidney disease pipeline, including povetacicept and inaxaplin, is seen as a multi-billion-dollar growth driver. Positive late-stage data and a rolling FDA submission for povetacicept could diversify revenue beyond cystic fibrosis, lifting long-term sales expectations.
This is a new growth opportunity that expands Vertex's revenue base and supports a higher valuation.
Casgevy approved for young children The FDA approved Casgevy for children as young as 2, expanding the market by about 5,500 U.S. patients and a $12.1 billion commercial opportunity. This regulatory win boosts Vertex's gene therapy revenue potential and strengthens its diversification story.
A major regulatory expansion directly increases the addressable market and future sales for a key Vertex product.
Vertex to buy Crinetics for $10 billion Vertex agreed to acquire Crinetics Pharmaceuticals for about $10 billion, adding the acromegaly drug paltusotine and other assets. The deal is expected to immediately boost revenue and contribute to operating profit by 2029, with over $5 billion in peak annual revenue potential.
This large acquisition expands Vertex's rare disease portfolio and provides near-term revenue growth, a key driver of the stock.
ALYFTREK gains Canadian reimbursement Vertex signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, making about 3,800 cystic fibrosis patients in Canada eligible. This expands access to Vertex's newest CF therapy, supporting incremental revenue growth in a core franchise.
New reimbursement expands the market for a key cystic fibrosis product, directly supporting Vertex's revenue.

June 202619 Jun – 10 Jul 2026

▲4

Vertex expands kidney, gene therapy, and rare disease reach

Kidney pipeline could add billions Vertex's kidney disease pipeline, including povetacicept and inaxaplin, is seen as a multi-billion-dollar growth driver. Positive late-stage data and a rolling FDA submission for povetacicept could diversify revenue beyond cystic fibrosis, lifting long-term sales expectations.
This is a new growth opportunity that expands Vertex's revenue base and supports a higher valuation.
Casgevy approved for young children The FDA approved Casgevy for children as young as 2, expanding the market by about 5,500 U.S. patients and a $12.1 billion commercial opportunity. This regulatory win boosts Vertex's gene therapy revenue potential and strengthens its diversification story.
A major regulatory expansion directly increases the addressable market and future sales for a key Vertex product.
Vertex to buy Crinetics for $10 billion Vertex agreed to acquire Crinetics Pharmaceuticals for about $10 billion, adding the acromegaly drug paltusotine and other assets. The deal is expected to immediately boost revenue and contribute to operating profit by 2029, with over $5 billion in peak annual revenue potential.
This large acquisition expands Vertex's rare disease portfolio and provides near-term revenue growth, a key driver of the stock.
ALYFTREK gains Canadian reimbursement Vertex signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, making about 3,800 cystic fibrosis patients in Canada eligible. This expands access to Vertex's newest CF therapy, supporting incremental revenue growth in a core franchise.
New reimbursement expands the market for a key cystic fibrosis product, directly supporting Vertex's revenue.

19 Jun – 10 Jul 2026

▲4

Vertex expands kidney, gene therapy, and rare disease reach

Kidney pipeline could add billions Vertex's kidney disease pipeline, including povetacicept and inaxaplin, is seen as a multi-billion-dollar growth driver. Positive late-stage data and a rolling FDA submission for povetacicept could diversify revenue beyond cystic fibrosis, lifting long-term sales expectations.
This is a new growth opportunity that expands Vertex's revenue base and supports a higher valuation.
Casgevy approved for young children The FDA approved Casgevy for children as young as 2, expanding the market by about 5,500 U.S. patients and a $12.1 billion commercial opportunity. This regulatory win boosts Vertex's gene therapy revenue potential and strengthens its diversification story.
A major regulatory expansion directly increases the addressable market and future sales for a key Vertex product.
Vertex to buy Crinetics for $10 billion Vertex agreed to acquire Crinetics Pharmaceuticals for about $10 billion, adding the acromegaly drug paltusotine and other assets. The deal is expected to immediately boost revenue and contribute to operating profit by 2029, with over $5 billion in peak annual revenue potential.
This large acquisition expands Vertex's rare disease portfolio and provides near-term revenue growth, a key driver of the stock.
ALYFTREK gains Canadian reimbursement Vertex signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, making about 3,800 cystic fibrosis patients in Canada eligible. This expands access to Vertex's newest CF therapy, supporting incremental revenue growth in a core franchise.
New reimbursement expands the market for a key cystic fibrosis product, directly supporting Vertex's revenue.